Dec. 13, 2024	Teijin Pharma Limited Applies for Manufacturing and Marketing Approval in Japan for New Hypoparathyroidism Treatment
Apr. 10, 2024	Teijin Pharma Grants Global Exclusive License to Bioprojet to Develop a New Orexin Receptor 2 Agonist Investigational Candidate for Narcolepsy
Feb. 13, 2024	Teijin and Axcelead to Determine the Name of Drug Discovery Research JV

Page Top